Herceptin, an aggressive anti-breast cancer therapy drug is well known to cause heart problems in patients with breast cancer
. But this drug when taken along with a combination of a chemotherapy drug called doxorubicin and an antihypertensive drug, it can reduce the risk of heart problems.
‘Herceptin, an aggressive anti-breast cancer therapy drug is well known to cause heart problems in patients with breast cancer.But this drug when taken along with a combination of a chemotherapy drug called doxorubicin and an antihypertensive drug, it can reduce the risk of heart problems.
The findings of this study are going to presented at the American College of Cardiology's 67th Annual Scientific Session.
A new standard of care has been developed to reduce the risk of cardiotoxicity in patients undergoing treatment for HER2-positive breast cancer.
FDA first approved Herceptin to treat an aggressive form of cancer- HER2-positive breast cancer. It had proved to be a stunning success in reducing cancer recurrence and improve survival rate, but due to its heart problem causing nature, physicians stopped prescribing Herceptin treatment or reduced the frequency of treatment if a patient's ejection fraction (a measure of the heart's ability to pump blood) was less then fifty percent.
The American Heart Association has warned doctors and patients to consider heart risks associated with Herceptin before they give or take the medication.
The placebo-controlled study explored whether two classes of drugs -- ACE inhibitors and beta blockers-- preserved a patient's cardiac function during chemotherapy or not.
The study studied the patients who were treated with Herceptin alone and also patients who were treated with Herceptin after the first dosage of chemotherapy drug known as doxorubicin.
"Herceptin is arguably the most effective treatment for HER2-positive breast cancer. These patients are already anxious about their future. We don't want to avoid this exceptionally effective treatment just because it might cause damage to the heart." said Guglin.
The study showed that ACE inhibitors and beta blockers drugs did not help preserve ejection fraction in patients taking Herceptin alone.
However, they were a significant decrease in cardiotoxicity for patients taking either beta blockers or ACE inhibitors who received doxorubicin before Herceptin: cardiac event rates in the placebo group were 47 percent, compared to ACE inhibitors (37 percent) and beta blockers (31 percent).
"In the past few decades, we've made huge strides in successfully treating cancers that used to be very deadly for patients," said Dr. Mark Evers, director of the NCI-designated UK Markey Cancer Center. "But it's important to also think about the patient's future and to help them maintain the best possible quality of life. This study provides valuable information for oncologists who are treating patients with HER2-positive breast cancer, and may help shape the new standard of treatment for this cancer in years to come," said Guglin.
"For example, should we always treat with both doxorubicin and Herceptin? Should we re-evaluate our minimum standards for heart function? What if the patient's EF is less than 50 percent but is asymptomatic? And should the patient's wishes carry more weight in the equation?" Guglin said.
"All of these questions require careful consideration, but this part is clear: giving an ACE inhibitor or beta blocker to patients taking doxorubicin and Herceptin for HER2-positive breast cancer will significantly reduce the risk of cardiotoxic side effects," said Dr. Maya Guglin.